scholarly journals Utilization of antipsychotic therapeutic drug monitoring at a state psychiatric hospital

2016 ◽  
Vol 6 (1) ◽  
pp. 1-7 ◽  
Author(s):  
Kara R. Wong ◽  
Leigh Anne Nelson ◽  
Ellie S. R. Elliott ◽  
Yifei Liu ◽  
Roger W. Sommi ◽  
...  

Abstract Introduction This study assesses the utilization of antipsychotic therapeutic drug monitoring (TDM) and describes characteristics of appropriate and inappropriate TDM at a state psychiatric hospital. Methods A retrospective, descriptive review was conducted for antipsychotic TDM completed between December 1, 2009, and June 30, 2011, at a 65-bed adult inpatient extended-care and forensic state psychiatric hospital. Results One hundred thirty-three (n = 133) antipsychotic serum levels were collected from 44 patients during the study period. Sixty-nine percent (69%) of the TDM were deemed inappropriate, 28% were appropriate, and 3% could not be designated appropriate or inappropriate owing to the lack of information regarding steady-state conditions. The primary reason for inappropriate TDM was lack of documentation with regard to the indication for TDM (n = 79, 59.3%), the intervention following laboratory analysis (n = 88, 66%), or both. Appropriate TDM was associated with a lower laboratory cost for antipsychotic serum level ($48.98 ± $53.49 versus $72.06 ± $51.02, P < .05), lower daily cost of scheduled psychiatric medications ($17.72 ± $23.03 versus $32.26 ± $31.05, P < .05), lower daily cost of total medications ($19.28 ± $24.91 versus $33.82 ± $31.03, P < .05), fewer scheduled psychiatric medications (2.95 ± 1.90 versus 4.04 ± 2.19, P < .01), and fewer total scheduled medications (5.95 ± 3.60 versus 7.60 ± 3.29, P < .05). Inappropriate TDM led to approximately $6,753 in avoidable laboratory costs over a 20-month period. Discussion Therapeutic drug monitoring is a complex process with many points at which errors may occur. The majority of antipsychotic levels at this state psychiatric hospital were not documented in a way that was clinically useful. Inappropriate TDM was associated with increased laboratory and medication costs.

2021 ◽  
Vol 37 (3) ◽  
pp. 187-192
Author(s):  
Kaveh Eslami ◽  
Sasan Moogah ◽  
Reza Ganji ◽  
Farhad Najmeddin ◽  
Sorour Moogahi

Author(s):  
Fanny Leenhardt ◽  
Matthieu Gracia ◽  
Catherine Perrin ◽  
Claudia Muracciole-Bich ◽  
Bénédicte Marion ◽  
...  

2016 ◽  
Vol 26 ◽  
pp. S585-S586
Author(s):  
V. Poinsignon ◽  
T. Poinsat ◽  
S. Raymond ◽  
M. Astier ◽  
C. Verstuyft ◽  
...  

2016 ◽  
Vol 54 (4) ◽  
pp. 353-360 ◽  
Author(s):  
Jesús Guinea ◽  
Pilar Escribano ◽  
Laura Judith Marcos-Zambrano ◽  
Teresa Peláez ◽  
Marta Kestler ◽  
...  

2015 ◽  
Vol 9 (2) ◽  
pp. 41-44
Author(s):  
Massimo Calderazzo ◽  
Pierandrea Rende ◽  
Paolo Gambardella ◽  
Manuela Colosimo ◽  
Giovambattista De Sarro ◽  
...  

We describe a 67-year-old man with medical history of focal post-stroke seizure and type 2 diabetes mellitus treated with carbamazepine, clobazam, gliclazide, insulin glargine, and omeprazole we visited for the onset in the last 7 days of asthenia, cough with mucus, breathing difficulty, chest pain, and weight loss. After clinical and laboratory tests, pulmonary tuberculosis was diagnosed, and a treatment with isoniazid, ethambutol, pyrazinamide rifampicin, and pyridoxine was started. Therapeutic drug monitoring of tuberculosis treatment documented that all drugs were in normal therapeutic range. Four days after the beginning of the treatment, we documented the improvement of fever, and three days later the patient showed sleepiness, visual disorder and asthenia. Clinical and pharmacological evaluation suggested a carbamazepine toxicity probably related to a drug interaction (Drug Interaction Probability Scale score = 6). The impossibility to switch carbamazepine for another antiepileptic drug, due to a resistant form of seizure, induced the discontinuation of tuberculosis treatment, resulting in the normalization of serum carbamazepine levels in one day (10 µg/ml) and in the worsening of fever, requiring a new clinical and pharmacological evaluation. The titration dosage of carbamazepine and its therapeutic drug monitoring allowed to continue the treatment with both antitubercular drugs and carbamazepine, without the development of adverse drug reactions. To date, tuberculosis treatment was stopped and clinical evaluation, radiology and microbiology assays documented the absence of tubercular infection and no seizures appeared (carbamazepine dosage 800 mg/bid; serum levels 9.5 µg/ml).


Sign in / Sign up

Export Citation Format

Share Document